News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Affymetrix (Santa Clara, California) (AFFX) Announces Research Collaboration with Massachusetts General Hospital to Validate and Develop New Oncology Biomarker Tests


6/6/2012 10:10:18 AM

SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix, Inc. (NASDAQ:AFFX) today announced a research collaboration and licensing agreement with Massachusetts General Hospital (MGH) to co-develop new cancer biomarker tests using the Affymetrix’ QuantiGene® ViewRNA Assay platform*, an in situ hybridization assay capable of single transcript in single-cell detection. As part of this agreement, Affymetrix has the rights to commercialize the new biomarker tests as an outcome of this collaboration.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES